Arrhythmias caused by platelet activating factor

Journal of Cardiovascular Electrophysiology

Volumn 7, Issue 2, 1996, Pages 120-133

  Hoffman, Brian F ^a   Guo, Shi Duo ^a   Feinmark, Steven J ^a  

^a Columbia University ^*  (United States)

Author keywords

arrhythmias; early afterdepolarizations; ischemia; neutrophils; platelet activating factor; reperfusion

Indexed keywords

THROMBOCYTE ACTIVATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARRHYTHMOGENESIS; ARTICLE; CELL ADHESION; DOSE RESPONSE; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART REPOLARIZATION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 0030050363     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1996.tb00507.x     Document Type: Article

References (54)

1. Wit AL, Janse MJ: The Ventricular Arrhythmias of Ischemia and Infarction: Electrophysiological Mechanism. Futura Publishing Company, Inc., Armonk, NY, 1993.
2. Janse MJ, Kleber AG: Electrophysiological changes and ventricular arrhythmias in the early phase of regional myocardial ischemia. Circ Res 1981;49:1069-1081.
3. Kleber AG: Resting membrane potential, extracellular potassium activity and intracellular sodium activity during acute global ischemia in isolated perfused guinea-pig hearts. Circ Res 1983;52:442-450.
4. Janse MJ, Wit AL: Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-1165.
5. McHowat J, Yamada KA, Wu J, et al: Recent insights pertaining to sarcolemmal phospholipid alterations underlying arrhythmogenesis in the ischemic heart. J Cardiovasc Electrophysiol 1993;4:288-310.
6. Manning AJ, Hearse DJ: Reperfusion-induced arrhythmias: Mechanisms and prevention. J Moll Cell Cardiol 1984;16:497-518.
7. 2+ and tension in isolated ferret ventricular muscle. J Physiol 1989;410: 297-323.
8. Corr PB, Cain ME, Witkowski FX, et al: Potential arrhythmogenic electrophysiological derangements in canine Purkinje fibers induced by lysophosphoglycerides. Circ Res 1979;44:822-832.
9. Arnsdorf MF, Sawicki GJ: The effects of lysophosphatidylcholine, a toxic metabolite of ischemia, on the components of cardiac excitability in sheep Purkinje fibers. Circ Res 1981;49:16-30.
10. Pogwizd SM, Onufer JR, Kramer JB, et al: Induction of delayed after-depolarizations and triggered activity in canine Purkinje fibers by lysophosphoglycerides. Circ Res 1986;59:416-426.
11. Clarkson CW, Ten Eick RE: On the mechanism of lysophosphatidylcholine-induced depolarization of cat ventricular myocardium. Circ Res 1983;52:543-556.
12. Kiyosue T, Arita M: Effects of lysophosphatidylcholine on resting potassium conductance of isolated guinea pig ventricular cells. Pflügers Arch 1986;406:296-302.
13. Undrovinas AL, Fleidervish IA, Makielski JC: Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res 1992;71:1231-1241.
14. Friedman PL, Stewart JR, Fenoglio JJ Jr, et al: Survival of subendocardial Purkinje fibers after extensive myocardial infarction in dogs: In vitro and in vivo correlations. Circ Res 1973;33:597-611.
15. Lazarra R, El-Sherif N, Scherlag BJ: Electrophysiological properties of canine Purkinje cells in one day old myocardial infarction. Circ Res 1973;33:722-734.
16. + activity, intracellular Na activity and maximum diastolic potential of canine subendocardial Purkinje cells from one-day-old infarcts. Circ Res 1987;60:122-132.
17. + and pH of subendocardial Purkinje cells during the first 24 hours after coronary occlusion. Circ Res 1992;70:566-575.
18. Hoffman BF, Ren X-L: Reversibility of electrophysiological abnormalities in subacute ischemia. PACE 1994;17(Pt II):2095-2099.
19. Ren XL, Hoffman BF: Reversibility of electrophysiological abnormalities of subendocardial Purkinje fibers induced by ischemia. J Cardiovasc Electrophysiol 1994;5:412-421.
20. Engler RL, Dahlgren MD, Peterson MA, et al: Accumulation of polymorphonuclear leukocytes during 3h experimental myocardial ischemia. Am J Physiol 1986;251:H93-H100.
21. Go LO, Murry CE, Richard VJ, et al: Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury. Am J Physiol 1988;255:H188-H198.
22. Dreyer WJ, Michael LH, West MS, et al: Neutrophil accumulation in ischemic canine myocardium. Circulation 1991;84:400-411.
23. Dreyer WJ, Michael LH, West MS, et al: Neutrophil accumulation in ischemic canine myocardium. Circ Res 1991;84:400-411.
24. Entman ML, Youker K, Shappell SB, et al: Neutrophil adherence to isolated adult canine myocytes. Evidence for a CD18-dependent mechanism. J Clin Invest 1985;85:1497-1506.
25. Entman ML, Youker K, Shappell SB, et al: Neutrophil adherence to isolated canine myocytes. J Clin Invest 1990;85:1497-1596.
26. Ferrier GR, Moffat MP, Lukas A: Possible mechanisms of ventricular arrhythmias elicited by ischemia followed by reperfusion. Studies on isolated canine ventricular tissues. Circ Res 1985;56:184-194.
27. Lucchesi BR, Mullane KM: Leukocytes and ischemia-induced myocardial injury. Annu Rev Pharmacol Toxicol 1986;26:201-224.
28. Ronson JL, Hook BG, Kunkel SL, et al: Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 1983;67:1016-1023.
29. Simpson PJ, Mickelson J, Fantone JC, et al: Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res 1987;60:666-673.
30. Aversano T, Zhou W, Nedelman M, et al: A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ishemia and reperfusion. J Am Coll Cardiol 1995;25: 781-788.
31. Dreyer WJ, Smith WC, Michael LH, et al: Canine neutrophil activation by cardiac lymph obtained during reperfusion of ischemic myocardium. Circ Res 1989; 65:1751-1762.
32. Guo S-D, Feinmark SJ, Hoffman BF: Interactions between activated neutrophils and activated cardiac myocytes. Circulation 1995;92(Suppl 1):450.
33. Terashita Z-I, Imura Y, Takatani M, et al: CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo. J Pharmacol Exp Ther 1987;242:263.
34. Prescott SM, Zimmerman GA, McIntyre TM: Platelet-activating factor. J Biol Chem 1990;265:17381-17384.
35. Sicouri S, Antzelevitch C: A subpopulation of cells with unique electrophysiological properties in the deep subepicardium of the canine ventricle. The M cell. Circ Res 1991;68:1729-1741.
36. Sicouri S, Fish J, Antzelevitch C: Distribution of M cells in the canine ventricle. J Cardiovasc Electrophysiol 1994;5:824-837.
37. Tessner TG, O'Flaherty JT, Wykle RL: Stimulation of platelet-activating factor synthesis by a nonmetabolizable bioactive analog of platelet-activating factor and influence of arachidonic acid metabolites. J Biol Chem 1989;264:4794-4799.
38. Feuerstein G, Goldstein RE: Effect of PAF on the cardiovascular system. In Snyder F, ed: Platelet Activating Factor and Related Lipid Mediators. Plenum Press, New York, 1987, pp. 403-424.
39. Wu J, Corr PB: Influence of long chain acylcarnitine on the voltage-dependent calcium current in adult ventricular myocytes. Am J Physiol 1992;263:H410-417.
40. Corr PB, Witkowski FX: Potential electrophysiologic mechanisms responsible for dysrhythmias associated with reperfusion of ischaemic myocardium. Circulation 1983;68(Suppl I):I-16-I-24.
41. Manning AS, Hearse DJ: Reperfusion-induced arrhythmias: Mechanisms and prevention. J Mol Cell Cardiol 1984;16:497-518.
42. Tzivoni D, Keren A, Granot H, et al: Ventricular fibrillation caused by myocardial reperfusion in Prinzmetal's angina. Am Heart J 1983;105:323-325.
43. Robinson LA, Braimbridge MV, Hearse DJ: Creatine phosphate: An additive myocardial protective and antiarrhythmic agent in cardioplegia. J Thorac Cardiovasc Surg 1984;87:190-200.
44. Goldberg S, Greenspoon AJ, Urban PL, et al: Reperfusion arrhythmias: A marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarction. Am Heart J 1983;105:26-32.
45. Squadrito F, Ioculano M, Altavilla D, et al: Platelet activating factor interaction with tumor necrosis factor in myocardial ischaemia-reperfusion injury. J Lipid Mediat 1993;8:53-65.
46. Braquet P, Pauber-Braquet M, Koltai M, et al: Is there a case for PAF antagonists in the treatment of ischemic states? TiPS 1989;10:23-30.
47. Chakrabarty S, Fluck DS, Flores NA, et al: Effects of the PAF antagonists BN50726 and BN50739 on arrhythmogenesis and extent of necrosis during myocardial ischaemia/reperfusion in rabbits. Br J Pharmacol 1992;107:705-709.
48. Sawa Y, Schaper J, Roth M, et al: Platelet-activating factor plays an important role in reperfusion injury in myocardium. Efficacy of platelet-activating factor receptor antagonist (CV-3988) as compared with leukocyte-depleted reperfusion. J Thorac Cardiovasc Surg 1994;108:953-959.
49. Tamura K, Kimura Y, Tamura T, et al: The effect of platelet-activating-factor antagonist TCV-309 on arrhythmias and functional recovery during myocardial reperfusion. Coron Artery Dis 1994;5:267-273.
50. Vera Z, Pride HP, Zipes DP: Reperfusion arrhythmias: Role of early afterdepolarizations studied by monophasic action potential recordings in the intact canine heart during autonomically denervated and stimulated states. J Cardiovasc Electrophysiol 1995;6:532-543.
51. Priori SG, Mantica M, Napolitano C, et al: Early after-depolarizations induced in vivo by reperfusion of ischemic myocardium. A possible mechanism for reperfusion arrhythmias. Circulation 1990;81:1911-1920.
52. Yamauchi-Pakihara K, Ihara Y, Ogata A, et al: Hypoxic stress induces cardiac myocyte-derived interleukin-6. Circulation 1995;91:1520-1524.
53. Go LO, Murry CE, Richard VJ, et al: Myocardial neutrophil accumulation during reperfusion after reversible or irreversible ischemic injury. Am J Physiol 1988;255(Heart Circ Physiol 24):H1188-H1198.
54. Youker K, Smith CW, Anderson DC, et al: Neutrophil adherence to isolated adult cardiac myocytes: Induction by cardiac lymph collected during ischemia and reperfusion. J Clin Invest 1992;89:602-609.